RU2001116558A - NUCLEIC ACID CARRIERS AND PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY - Google Patents

NUCLEIC ACID CARRIERS AND PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY

Info

Publication number
RU2001116558A
RU2001116558A RU2001116558/14A RU2001116558A RU2001116558A RU 2001116558 A RU2001116558 A RU 2001116558A RU 2001116558/14 A RU2001116558/14 A RU 2001116558/14A RU 2001116558 A RU2001116558 A RU 2001116558A RU 2001116558 A RU2001116558 A RU 2001116558A
Authority
RU
Russia
Prior art keywords
nucleic acid
gene therapy
pharmaceutical compositions
polypeptide
acid carriers
Prior art date
Application number
RU2001116558/14A
Other languages
Russian (ru)
Inventor
Такеси ГОТО
Кейси ЙОНЕМУРА
Тецудзи КУВАХАРА
Масанао ОЙА
Кацухико АКИЯМА
Original Assignee
Хисамицу Фармасьютикал Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хисамицу Фармасьютикал Ко., Инк. filed Critical Хисамицу Фармасьютикал Ко., Инк.
Publication of RU2001116558A publication Critical patent/RU2001116558A/en

Links

Claims (4)

1. Носитель нуклеиновой кислоты, содержащий полипептид, имеющий число остатков от 20 до 280 и указанный полипептид получен поликонденсацией мономера диаминомасляной кислоты и/или его фармацевтически приемлемую соль.1. A nucleic acid carrier containing a polypeptide having a residue number of from 20 to 280 and said polypeptide is obtained by polycondensation of a diaminobutyric acid monomer and / or a pharmaceutically acceptable salt thereof. 2. Носитель нуклеиновой кислоты, содержащий блоксополимер полипептида и полиэтиленгликоля и указанный полипептид получен поликонденсацией мономера диаминомасляной кислоты и/или его фармацевтически приемлемую соль. 2. A nucleic acid carrier comprising a block copolymer of a polypeptide and polyethylene glycol and said polypeptide is obtained by polycondensation of a diaminobutyric acid monomer and / or a pharmaceutically acceptable salt thereof. 3. Фармацевтическая композиция для генной терапии, содержащая носитель нуклеиновой кислоты по п. 1 или 2 и терапевтический ген. 3. A pharmaceutical composition for gene therapy, comprising a nucleic acid carrier according to claim 1 or 2 and a therapeutic gene. 4. Фармацевтическая композиция для генной терапии по п. 3, где терапевтический ген является нуклеиновой кислотой и/или нуклеотидным производным. 4. The pharmaceutical composition for gene therapy according to claim 3, wherein the therapeutic gene is a nucleic acid and / or nucleotide derivative.
RU2001116558/14A 1998-11-18 1999-11-17 NUCLEIC ACID CARRIERS AND PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY RU2001116558A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10/328126 1998-11-18

Publications (1)

Publication Number Publication Date
RU2001116558A true RU2001116558A (en) 2003-04-20

Family

ID=

Similar Documents

Publication Publication Date Title
IL101650A0 (en) Sulphonamides,their manufacture and pharmaceutical compositions containing them
CA2260213A1 (en) Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
FR2738151B1 (en) ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE MDM2 PROTEIN, AND THEIR USE IN THE TREATMENT OF CANCERS
CA2234610A1 (en) New amino acid derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
IE891542L (en) Peptides having t cell helper activity
RU97108698A (en) INTERFERON CONJUGATES
EP0333174A3 (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
CA2316921A1 (en) Aryl fused azapolycyclic compounds
CA2316539A1 (en) Sustained-release pharmaceutical composition
ATE206716T1 (en) CYCLIC PRODUCERS COMPOUNDS OF PEPTIDES AND PEPTIDE-NUCLIC ACIDS WITH IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY
RU2002102701A (en) Stable oral hydrogel-forming, pharmaceutical composition, method for its preparation, method for preventing changes in drug release, method for increasing physical stability of the oral composition
SE9902987D0 (en) Novel compounds
CN101304748A (en) Tlr agonists
CA2238859A1 (en) Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
EP0994850B1 (en) Inhibition of hiv-1 replication using oligocarbamate derivatives
RU93058449A (en) HCV GENOMIC SEQUENCES FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
FI891361A (en) Process for the preparation of pharmaceutically active arylhydrazones
BR0007589A (en) Cell proliferation inhibitors
RU2001124840A (en) ANTITUMER ANTISEMIC SEQUENCES AIMED AT COMPONENTS R1 AND R2 OF RIB NUCLEOTID REDUCASE
ES8502417A1 (en) Pharmaceutical composition comprising phenyl acetyl glutamine,a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)piperidine-2,6-dione,a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)piperidine-2,6-dione.
IL94452A0 (en) Aryloxyphenylpropylamines,their preparation and pharmaceutical compositions containing them
EP0646596B1 (en) Nucleic acid binding oligomers having C-branches for therapy and diagnosis
CA2395493A1 (en) Hyaluronic acid in the treatment of cancer
IT1299583B1 (en) USE OF HMG-I PROTEIN FOR THE PREPARATION OF MEDICATIONS WITH CYTOTOXIC ACTIVITY
RU96104348A (en) AIDS PREVENTION